Agile Therapeutics

Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patch. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Agile Therapeutics is a specialty pharmaceutical company that engages in the development of women's healthcare products. It offers a low estrogen dose seven-day transdermal contraceptive patch system that delivers a combination of levonorgestrel and ethinylestradiol. This is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today’s women.

PRINCETON, N.J., April 30, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that a post hoc analysis of the Phase 3 SECURE Trial evaluating the safety and efficacy of Twirla® (levonorgestrel and ethinyl estradiol) transdermal system in women with BMI < 25 kg/m2 and women with BMI 25-30 kg/m2 will be presented at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting from April 30 – May 2.

Agile Therapeutics Announces Presentation of Safety and Efficacy Data of Twirla® (Levonorgestrel and Ethinyl Estradiol) Transdermal System in Women of Differing BMI Categories at ACOG Annual Meeting

PRINCETON, N.J., April 20, 2021 (GLOBE NEWSWIRE) -- In a release issued earlier today by Agile Therapeutics, Inc. (Nasdaq: AGRX), please note the headline should read "Agile Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on Tuesday, May 4, 2021" instead of "Agile Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on Tuesday, May 4, 2020". The corrected release follows:

CORRECTING AND REPLACING -- Agile Therapeutics

Live Conference Call and Webcast at 4:30 p.m. EDT Live Conference Call and Webcast at 4:30 p.m. EDT

Agile Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on Tuesday, May 4, 2020

Checkmate Pharmaceuticals

Cyclo Therapeutics, Inc.

Gold Resource

Rhythm Pharmaceuticals

Windtree Therapeutics

William Penn Bancorp

Insider buying could be a bullish sign for a stock. Insiders may sell their shares for many reasons.

7 Beaten Down Stocks with Significant Insider Buying

Aqua Metals

Catabasis Pharmaceuticals

Checkpoint Therapeutics

Hepion Pharmaceuticals Inc

InflaRx

Limelight Networks

Investors in penny stocks know the prices of many have crashed. But these seven stocks may have room to run higher.

7 Penny Stocks That May Have Room to Run Higher

PRINCETON, N.J., March 05, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairman and Chief Executive Officer Al Altomari will present at two investor conferences in March.

Agile Therapeutics to Present at Upcoming March Investor Conferences

Agile Therapeutics, Inc. (AGRX) CEO Alfred Altomari on Q4 2020 Results - Earnings Call Transcript

Perceptive Advisors Increases Credit Facility to $45 million, with $25 million potentially available

Agile Therapeutics Reports Fourth Quarter & Full Year 2020 Financial Results; Expands Loan Facility With Perceptive Advisors

Live Conference Call and Webcast at 4:30 p.m. ET

Agile Therapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Provide Corporate and Twirla Commercial Updates on Monday, March 1, 2021

Agile Therapeutics' recently approved Twirla patch is starting to hit the market. The company's market cap is significantly lower than it was a year ago.

What's Happening At Agile

PRINCETON, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced Chairman and Chief Executive Officer Al Altomari will participate in a fireside chat at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference.

Agile Therapeutics to Participate in Fireside Chat at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference

PRINCETON, N.J., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced the Company will present at the 39th Annual J.P. Morgan Healthcare Conference, which is being held virtually, on Thursday, January 14, 2021, at 9:10 a.m. ET.

Agile Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

Agile Therapeutics is preparing to launch their first FDA approved product, Twirla. If all goes well, Twirla could quickly establish a foothold in a $4.1B addressable market. Launching an FDA approved product is not easy and has plenty of unknowns. I point out some things to keep an eye out for before and after Twirla's launch.

Agile Therapeutics: Managing A Position Ahead Of Twirla's Launch

Once-Weekly Twirla is the first and only contraceptive patch that combines levonorgestrel and ethinyl estradiol (EE)

Agile Therapeutics Announces Nationwide Commercial Launch and Availability of Twirla® (levonorgestrel and ethinyl estradiol) Transdermal System, a New Non-Daily, Non-Invasive Contraceptive Patch

PRINCETON, N.J., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Contraception, an international, peer-reviewed, reproductive health journal, published the primary safety, efficacy, and tolerability results from the Phase 3 SECURE study evaluating Twirla® (levonorgestrel and ethinyl estradiol) transdermal system. The results have been published online in Contraception (https://bit.ly/SECUREStudy) and will also appear in a future print edition of the journal.

Agile Therapeutics Announces Peer-Reviewed Publication of Phase 3 SECURE Study Results for Twirla® (levonorgestrel and ethinyl estradiol) Transdermal System in Contraception

PRINCETON, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Al Altomari, Chairman and Chief Executive Officer, will participate in a virtual fireside chat at the Piper Sandler 32nd Annual Healthcare Conference, being held December 1-3, 2020.

Agile Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference

The drugmaker will soon give Twirla a twirl.

Agile Therapeutics' Q3 Focused on Launching Its New Contraceptive Patch

Agile Therapeutics, Inc. (AGRX) CEO Alfred Altomari on Q3 2020 Results - Earnings Call Transcript

Commercial Launch of Twirla® Expected by Year-End 2020

Agile Therapeutics Reports Third Quarter 2020 Financial Results

Agile Therapeutics to Host Third Quarter 2020 Financial Results Conference Call and Provide Corporate and Twirla® Commercial Updates on Thursday, November 12, 2020

PRINCETON, N.J., Sept.  22, 2020  (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairman and CEO Al Altomari will be virtually presenting at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Wednesday, September 23, 2020 at 3:20 PM EDT.

Agile Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

PRINCETON, N.J., Sept.  09, 2020  (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a forward-thinking women’s healthcare company, today announced that Al Altomari, Chairman and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 22nd Annual Global Investment Virtual Conference on Wednesday, September 16, 2020 at 11:30 a.m. EDT.

Agile Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 22nd Annual Global Investment Virtual Conference

Company to Present Twirla® Commercial Plan

Agile Therapeutics Announces Virtual Investor/Analyst Day on Monday, September 21, 2020

Visit BirthControlDoneMyWay.com to learn more about some of the many available contraceptive options

Agile Therapeutics Launches I’m So Done Campaign to Inspire Women to Take an Active Role in Choosing their Birth Control

PRINCETON, N.J., Aug.  17, 2020  (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a forward-thinking women’s healthcare company, today announced the appointment of Paul Korner, MD, MBA, to the position of Chief Medical Officer. Dr. Korner is a board-certified obstetrician and gynecologist with more than 20 years of pharmaceutical and biotech industry experience, including significant experience within women’s healthcare. He will be responsible for supporting the commercial launch of Twirla®, advancing the Company’s internal pipeline and evaluating external growth opportunities. Dr. Korner will report to Al Altomari, Agile’s Chairman and Chief Executive Officer.

News for Agile Therapeutics Stock (AGRX)